SMARCD3 and Alzheimer disease: Furthermore, the mRNA levels of RPL37A (p < 0.0010), RPL5 (p = 0.0084), PPP1CB (p < 0.0010), RPL24 (p < 0.0010), THRA (p < 0.0010), CASP2 (p = 0.0077), SMARCD3 (p < 0.0010), NLN (p < 0.0010), MSH5 (p < 0.0010), and EPDR1 (p = 0.0099) genes were significantly lower in the patients with AD than in the NEC group (Figure 3b), and the change in expression of these genes was in direct contrast to the results of the GSE data analysis.